BioSpace News Archive

AstraZeneca - Heart failure and asthma studies will pilot a new digital health platform to help improve outcomes for patients with chronic diseases

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a clinical study of TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR).

- Data further demonstrate proof-of-concept for the therapeutic potential of apitegromab in patients with Type 2 and Type 3 SMA - Phase 3 registrational trial initiation expected by the end of 2021 - European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to apitegromab, recognizing unmet medical needs of patients with SMA

Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the 20 th Annual Needham Virtual Healthcare Conference. David A. Weber, Ph.D., president and CEO of Otonomy, will present a company overview on Tuesday, April 13, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides

Extending its ongoing commitment to caregivers through the Caregiver-Friendly Pharmacy program, and recognizing the significant toll COVID-19 has had on the caregiver community over the past year, Teva Canada unveiled new resources and programming to support the mental health challenges caregivers often experience.

Moleculin Biotech, Inc., today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company’s effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

NeuPath Health Inc. (TSXV:NPTH) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, today announced Grant Connelly, CEO, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.

Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on recent FDA feedback and ongoing interactions Clinical expansion efforts underway for elamipretide in rare metabolic cardiomyopathies and in rare mitochondrial disease caused by nuclear DNA mutations